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WHAT THIS PAPER ADDS
 This is the ﬁrst randomised trial on acute dissection. It compares best medical treatment (BMT) with BMT and stent grafting of the
primary entry tear in patients having acute uncomplicated type B aortic dissection. Patients are randomised within 14 days of the
onset of symptoms.
 The study is a multicentre European trial with a clear deﬁnition of uncomplicated dissection with a double lumen in the thoracic
aorta. Patients with malperfusion, rupture, penetrating ulcer and intramural haematoma are excluded.
 The study will bring evidence as to whether stent grafting will produce thrombosis and remodelling of the false lumen with
a reduction in aneurysm formation and re-intervention.a r t i c l e i n f o
Article history:
Received 29 November 2011
Accepted 26 March 2012







Outcome* Corresponding author. J. Brunkwall, Department o
Clinics, Kerpener Str. 62, 50931 Cologne, Germany
fax: þ49 221 4787241.
E-mail address: jan.brunkwall@uk-koeln.de (J. Bru
e For the ADSORB trialists.
1078-5884/$ e see front matter  2012 European So
doi:10.1016/j.ejvs.2012.03.023a b s t r a c t
Acute dissection of the descending thoracic aorta carries a 30-day mortality of around 10% with best
medical treatment (BMT). In addition, about 25% will develop an aneurysm during the following 4e5
years.
This is the ﬁrst ever randomised trial on acute dissections comparing BMT with BMT and stent grafting
of the proximal tear in patients having an uncomplicated acute dissection of the descending aorta. The
commonly used temporal deﬁnition of acute dissection being within 14 days of onset of symptoms is
applied.
A total of 61 patients will be randomised and followed at regular intervals (1, 3, 6, 12, 18, 24, 30 and 36
months) after acute dissection. Thrombosis of the false lumen, aortic enlargement and rupture are the
primary end points.
The study will examine whether aortic remodelling occurs after stent grafting in acute type
B dissections, and its effect on aneurysm formation, rupture and re-intervention.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Acute dissection of the ‘ascending’ aorta1 has a 55% mortality
during the ﬁrst 14 days, and requires prompt surgical therapy,2
which lowers the mortality to 20%. By contrast, acute dissection
of the ‘descending’ thoracic aorta carries a lower initial mortality,
but the mortality is higher if it is complicated by refractory pain,3
paraplegia, hypertension, lower limb ischaemia, haemothorax orf Vascular Surgery, University
. Tel.: þ49 221 47832501;
nkwall).
ciety for Vascular Surgery. Publisherupture.4The original classiﬁcation of acute dissection of the aorta
by DeBakey comprises DeBakey I (affecting both the ascending and
descending aorta), DeBakey II (only the ascending aorta) and
DeBakey III (IIIa including the descending aorta only, IIIb
descending aorta with involvement of the abdominal aorta).5 The
later more commonly used Stanford classiﬁcation (A; involving the
ascending aorta and B; only involving the descending aorta) does
not describe the entry tear, which is less helpful in the new era of
endovascular techniques.6
Endovascular repair is a viable alternative to open repair in the
treatment of both abdominal and thoracic aortic aneurysms
(thoracic endovascular aneurysm repair (TEVAR))7e9 and ind by Elsevier Ltd. All rights reserved.
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acute dissection by Dake et al. in 1994, several case and cohort
studies have demonstrated the feasibility and efﬁcacy of endovas-
cular repair for complicated acute dissection type DeBakey III,
including patients with malperfusion of the viscera, kidneys spinal
cord and the lower limbs.4 In addition, a meta-analysis showed
better results with TEVAR than open surgery.12
The evidence for TEVAR in acute dissection is from registry data
such as International Register on Acute Dissection (IRAD); however,
no systematic study on the effect of TEVAR for the treatment of
‘acute dissection’ has been published. The Interventional Stent
Treatment Acute Dissection (INSTEAD) trial included patients with
chronic dissection who presented from 2 weeks up till 1 year after
onset of symptoms. That study showed aortic remodelling during
follow-up over 2 years, but this had no statistically signiﬁcant effect
onmortality, as the study was not powered for that.13 The mortality
in acute DeBakey III dissections is highest within 10e14 days after
the acute onset, and thereafter the mortality rate decreases,2,14 but
many survivors need an aortic intervention as 25% of the patients
develop aortic dilatation/aneurysm.15
No level I evidence exists to support endovascular treatment of
acute uncomplicated DeBakey III dissections, and medical treat-
ment is still therefore considered the best treatment. The aim of the
present study is to compare best medical treatment (BMT) with
BMT plus thoracic stent grafting with respect to aortic remodelling
and re-intervention in patients with an uncomplicated acute
dissection of the descending aorta.Medical Treatment
Early outcome
The primary aim of BMT in DeBakey III is to reduce the blood
pressure to a level of around 120 mmHg systolic and 80 mmHg
diastolic, with preservation of urinary function. The preferred
medication is selective beta blockade, which lowers the
blood pressure by decreasing the force of left ventricular ejection
(dP/dt).16 Diuretics are used to decrease blood volume, as are
angiotensin-converting-enzyme (ACE) inhibitors and calcium
channel antagonists, and alpha blockade may be required in
refractory cases. A meta-analysis showed a reduction in 30-day
mortality with BMT from 40% in the 1960s to around 10% at
present.17Late outcome
The long-term risk of developing aneurysm and malperfusion
syndromes still exists despite effective medical therapy. The
IRAD study followed 342 patients, of which 189 had medical
therapy, 26 open surgery and 27 endovascular therapy. The 3-
year survival was 77.6  6.6%, 82.8  18.9% and 76.2  25.2%,
respectively.18 However, the groups were not comparable as
surgical or endovascular treatment was only used in patients
with complicated dissections, and BMT in uncomplicated
dissections. Another confounding factor was the inclusion of
patients with intramural haematoma making evaluation less
reliable. A study of 189 patients, with 111 being treated medi-
cally and the rest surgically, showed no difference between the
groups with a 1-year survival of 70% and a 5-year survival of
60%.19 In a recent study, the mortality after medical treatment
of DeBakey type III dissection was 10% although the number of
patients developing complications requiring intervention was
not given.20 In another publication, 14% of medically treated
patients required intervention.21Study Objectives
The objective of the acute dissection stent grafting or best
medical treatment (ADSORB) trial is to assess the safety and efﬁcacy
of BMT and endoluminal stent graft (TAG device) compared to
BMT alone in patients with acute uncomplicated type B (DeBakey
III) aortic dissection. The multicentre, prospective, randomised
controlled trial will be conducted in Europe and will randomise
patients to one of two treatment groups.
End point
Primary end point
The primary end point for this study is a composite of the
following events:
Incomplete or no false lumen thrombosis (FLT) at 1 year
Test Group: Incomplete thrombosis will be deﬁned as the pres-
ence of blood ﬂow in any portion of the false lumen parallel to the
stent graft, excluding the distal 2 cm; Complete thrombosis will be
deﬁned as absence of blood ﬂow in any portion of the false lumen
parallel to the stent graft, excluding the distal 2 cm; No FLT will be
deﬁned as the presence of blood ﬂow throughout the entire false
lumen within the descending thoracic aorta parallel to the stent
graft.
Control Group: Incomplete thrombosis will be deﬁned as the
presence of blood ﬂow in any portion of the false lumen at any
point in the descending thoracic aorta. Complete thrombosis will be
deﬁned as absence of blood ﬂow in any portion of the false lumen at
any point in the descending thoracic aorta. No FLTwill be deﬁned as
the presence of blood ﬂow throughout the entire false lumen
within the descending thoracic aorta.
Aortic dilatation at 1 year
An increase of 5 mm in the maximum diameter of the
descending thoracic aorta compared to thepre-treatment computed
tomography (CT) measurement or the maximum diameter of the
descending thoracic aorta 55 mm at the 1-year follow-up visit.
Aortic rupture (descending thoracic aorta or abdominal aorta)
through the 1-year follow-up visit
Disruption of the descending thoracic or abdominal aorta with
fresh blood outside the adventitia observed on CT, radiograph or
other radiological modalities at any time through the 1-year follow-
up visit.
Sample size calculation
Based on published calculations, the expected incidence of an
acute aortic dissection is three out of 100 000 persons.22,23 40% are
conﬁned to the descending aorta2 giving 1.2e2/100 000 persons/
year. The deﬁnition of an acute dissection is less well deﬁned in the
various publications where intramural haematoma and penetrating
aortic ulcers have been included. Only acute dissection with
a double lumen aorta will be included, and penetrating ulcer and
intramural haematoma will be excluded.
It was deduced from published series on acute aortic descending
thoracic dissection, that 35% of the patients treated medically
would thrombose the false lumen over a 1-year period. From the
IRAD data and other published series on TEVAR for acute compli-
cated dissections, it was deduced, that on average 55% of TEVAR-
treated patients would thrombose the false lumen.
Hypothesis
The null hypothesis upon which the study design was based is
that there will be no difference in the proportion of patients event
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alternative hypothesis is that the proportion of patients being event
free at 1 year will be greater for patients treated with stent grafts
and medical therapy than the medically managed patients alone.
Sample size calculation (initial design)
For the composite end point, it was assumed that the primary
difference between the groups would be largely determined by the
proportion of patients experiencing FLT. It was assumed that FLT in
medically managed subjects would be relatively infrequently
observed.
Therefore, the sample size calculation was based on the
following assumptions:
 pT, the test event proportion ¼ 0.35
 pC, the control event proportion ¼ 0.55
 Clinically meaningful target effect size (d ¼ pCpT) ¼ 0.20
 Signiﬁcance level (a) ¼ 0.05, two-sided
Under these assumptions, a sample size of 250 patients (125
per group) would provide 89% power to test the primary
hypothesis under the intent-to-treat analysis. This sample size
would also provide at least 85% power for the evaluation of the
test using the per protocol analysis, assuming a 10% rate of
protocol violations. These calculations assume the use of a two-
sided Chi-square test for the primary analysis of the 1-year end
point.
Sample size calculation (reduced sample size)
During the design of the TAG 05-04 (ADSORB) trial, much
uncertainty remained surrounding the end point event rate. Very
conservative estimates for FLT were therefore used in the sample
size calculation. During the recruitment phase of this study, two
things became apparent; ﬁrst it was realised that much fewer
patients than expected met the inclusion criteria and, secondly,
new studies on the thrombosis rate in BMT groups and after TEVAR
were published.13,15 This new information, in combinationwith the
slower than expected enrolment, led us to recalculate the sample
sizes as the enrolment period using the old methodology would be
more than 7 years.
Event rates for FLT for patients treated with a stent graft in
recently published studies were:
B TAG 04-01 e 86% FLT at 1 year (pT ¼ 0.14)
B INSTEAD e 91% FLT at 2 years (pT ¼ 0.09)
B Song et al. e 88% FLT at 1 year (pT ¼ 0.12)
 Medical patients
B INSTEAD e 21% FLT at 2 years (pC ¼ 0.79)
Given this, it was determined that ADSORB was overpowered at
250 patients and therefore it was re-designed to test the same
hypotheses with a smaller sample size, based on the following
assumptions. In addition, more patients would be enrolled than
were required which would be unethical.
 pT, the test event proportion ¼ 0.12
 pC, the control event proportion ¼ 0.70
 Clinically meaningful target effect size (d ¼ pCpT) ¼ 0.58
 Signiﬁcance level (a) ¼ 0.05, two-sided
A sample size of 60 patients (30 per group) would provide 86%
power to test the primary hypothesis under the intention-to-treat
analysis. This sample size also provides over 90% power for the
evaluation of the test using the per protocol analysis, assuming
a 10% rate of protocol violations. These calculations assume the useof a two-sided Chi-square test for the primary analysis of the 1-year
end point.
Primary end point analysis population
The analysis of the primary end point will be based upon the
intention-to-treat principle. All subjects randomised into the study
will be analysed for the 1-year primary end point as randomised,
regardless of actual treatment received. Any treatment crossovers
(e.g., BMT subjects who receive a GORE TAG device following ran-
domisation) will be includedwith the originally assigned treatment
group.
Patient Selection
BMT is normally started as soon as the diagnosis of aortic
dissection has been made. All eligible patients (see inclusion and
exclusion criteria below) will be requested to give informed
consent, both for treatment and for follow-up. Patients will
undergo laboratory and imaging studies to identify eligibility for
the study. If all inclusion and no exclusion criteria are met, patients
will be randomised immediately, which is designed to balance the
number of test and control patients.
Patients randomised to the test group will receive their treat-
ment within 48 h.
Clinical Study Plan
Patients will be evaluated pre-treatment, at discharge and will
return for follow-up visits at 1 month (7 days), 3 months (14
days), 6 months and every 6 months thereafter for 3 years. Chest X-
rays and CT scans are required either at discharge or at 1 month
follow-up visit. CT scans will be performed at 3 months and
annually thereafter. Patients in the control group will undergo
identical follow-up evaluations, with the exception of chest X-rays,
which will be performed only in the test group.
Morphological evaluation
The basis for the randomisation will be the judgement of the
treating physicians, and all the morphology data will be entered by
the treating physician. Fig. 1. An independent core lab situated in
Heidelberg will separately evaluate all CT scans to standardise
evaluation and reporting of the investigations. In this way, there
will be no delay in randomisation, but there will be a standardised
evaluation of all patients.
Discussion
The open surgical repair of acute dissection of the descending
thoracic aorta reported by DeBakey in 1955 and 1965 comprised
open fenestration, but the results were not encouraging. Closure of
the false lumen at the proximal tear became more popular and
improved outcome. Antihypertensive treatment has been shown to
be an effective treatment for uncomplicated DeBakey type III
dissection such that there is no role for open surgery in this setting.
In the acute phase, surgery may be indicated in patients with
overt or pending rupture of the thoracic aorta. This includes
replacing a section of the aorta with closure of the proximal tear
and false lumen. Open fenestration in combination with a bypass
procedure may rarely be necessary. In patients with ischaemic
complications such as visceral or renal ischemia or paraplegia, the
mortality of open surgery is high at 21e50%.24 Interventional
radiological techniques such as fenestration and stenting of the
branch vessel oriﬁces may produce good reperfusion as shown by
37 of 40 malperfused vessels being revascularised in one series;
Figure 1. (a) The protocol form for the measurements.
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deal with the dissection itself but only with the ischaemic
complications.
Dake et al. in 1994 ﬁrst reported using an endograft to treat
acute DeBakey type III aortic dissections.25 Endovascular repair
can effectively seal the proximal tear with thrombosis of the false
lumen in up to 90e98% of the cases.13,26 The rationale for endo-
vascular therapy is to close the primary entry tear causing pres-
sure reduction and thrombosis of the false lumen and restoring
the normal anatomy. False lumen obliteration is associated with
better long-term outcome in patients presenting with acute
dissection.21,27 Stent graft therapy could also result in less aneu-
rysm formation in the long term. However, the false lumen distal
to the device may not be thrombosed by the stent graft. The
reason for this is the presence of secondary tears in the distal
aorta, which perfuse the false lumen. The rate of complete oblit-
eration of the false lumen with apposition of the dissection ﬂap to
the outer wall after closure of the proximal tear is currently
unknown.
Several reports on the outcome of endovascular treatment of
DeBakey type III dissection have been published. A search of
PUBMED from 1990 and onwards, revealed 50 publications with
a total of 3990 patients who had a dissection of the thoracic
descending aorta. A total of 39 patients died immediately after
admission. One of the feared complications of open surgery is
paraplegia, which affected 6.6% in the open group and 2.4% in the
endovascular group and 0% of the group treated medically. The role
of endovascular treatment in uncomplicated acute aortic dissection
DeBakey type III (Stanford B) has not been scientiﬁcally addressed.The tissues in acute dissection are less rigid and ﬁbrotic so endo-
vascular repair may well result in aortic remodelling producing
a single lumen aorta especially at the site of the device.
The mortality in the BMT group is thus not insigniﬁcant at 10%,2
so the question arises as to whether endovascular treatment can
reduce mortality further. This question though will not be
answered by the present study. Furthermore, the optimal length to
cover with TEVAR will also not be answered by this study.
There are at present no randomised studies on this subject in the
literature. The ADSORB trial is currently recruiting patients and will
report on thrombosis of the false lumen and both dissection-related
and overall mortality after 1 and 3 years of follow-up.
Inclusion/Exclusion Criteria
Inclusion criteria
1. Presence of acute uncomplicated type B aortic dissection.
- Acute is deﬁned as time from symptom onset to diagnosis 14
days.
- Uncomplicated course includes freedom from:
B end-organ ischaemia or evidence of malperfusion.
B paraplegia.
B rupture (free or contained) or impending rupture.
B uncontrollable pain (minimal pain after initial medical
therapy is acceptable).
- Type B dissectionwhere the primary entry tear is distal to the left
subclavian artery with no involvement of the ascending aorta or
aortic arch.
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a dissection ﬂap and dual aortic lumens. Dissection variants such
as intramural haematoma and penetrating ulcer are not allowed
in this study.
2. Maximum transverse diameter of the descending thoracic
aorta <55 mm and absence of descending thoracic aortic
aneurysm, regardless of aetiology.
3. Arterial anatomy is appropriate for stent graft therapy,
deﬁned as:
4. Proximal landing zone is not aneurysmal, dissected or signiﬁ-
cantly thrombosed.
5. Proximal landing zone length 2.0 cm.
6. Proximal landing zone diameters between 23 and 42 mm.
7. Non-tortuous or non-stenotic iliac and/or femoral arteries or
ability to use a conduit for vascular access.
8. Able to tolerate endotracheal intubation and general
anaesthesia.
9. Age 18e80 years.
10. Declaration of voluntary participation in the study with signed
informed consent form.
11. Capable of complying with study protocol requirements,
including long-term medical treatment with beta blockers,
diuretics and/or ACE-inhibitors and follow-up for 3 years post-
randomisation (patient must have 3-year life expectancy and
ability to return for scheduled follow-up visits).
Exclusion criteria
1. American Society of Anesthesiologists (ASA) classiﬁcation ¼ V.
2. Severe renal insufﬁciency deﬁned as Society for Vascular
Surgery (SVS) risk renal status ¼ 3.
3. Severe respiratory insufﬁciency deﬁned as SVS risk pulmonary
status ¼ 3.
4. Presence of connective tissue disease (Marfan’s syndrome or
Ehlers-Danlos syndrome).
5. Active infection or active vasculitis.
6. Positive pregnancy test.
7. Participation in another medical research study within 3
months of study enrolment.
8. Myocardial infarction or cerebrovascular accident within 6
weeks prior to study enrolment.
9. Planned concomitant surgical procedures (other than left
subclavian artery transposition or bypass) or major surgery
within 30 days of study enrolment.
10. History of drug abuse.
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